Steini i find it a bit weird that the office girl would get back to you if newregime really rang. Firstly who is newregime and how would anyone really know if he rang if they don't know his real name. Many a shareholder would be ringing ANP to discuss the company as happens with most ASX listed companies daily and especially after news of the like of what ANP just released. I actually ring every company i invest in and at times try to make a face to face meeting if possible. I find the smaller the company the more likey this happens. I also make sure i try to go to every AGM or meeting to not only see what is happening but sometimes just a look at the way the directors speak and show passion for their company helps me to decide if i should invest more.
Anyway back to ANP wouldn't it be a better idea if you actually asked to speak to a director and discuss the actual announcement and what it meant by the pharma requesting to go into due diligence. I actually spoke to the company yesterday and asked these questions about the way forward from here. Simply i was told that this pharma is interested and ANP are discussing which way to move forward in the best interests of shareholders which there are numerous ways whether in a partnership through a licensing deal or not but they will continue to move forward with ATL1103 towards phase2a trial till a decision is made. They were very surprised that on this chat room that some had taken the announcement that ANP had knocked back the offer from this pharma to go into due diligence because they said they would continue to plan for the phase2a trial. Of course ANP will go forward business as usual till they decide on which direction to take. It clearly said ANP are entertaining the interest of the pharma company. Once again here is the extract forom the announcement which clearly states the above.
ANP also advises that subsequent to the Company’s trading halt, a Pharmaceutical Company that has previously expressed an interest in ATL103 has indicated to ANP its desire to move into licensing due diligence. While ANP is entertaining this interest from the Pharmaceutical Company, it has not committed to partnering ATL1103 at this stage of the drug’s development and will continue its planning to progress ATL1103’s development towards a Phase II clinical trial.
ANP Price at posting:
29.0¢ Sentiment: Buy Disclosure: Held
